“Defendants argue that neither the jury nor the court identified the misappropriated trade secrets, or found that the purloined trade secrets were actually exploited, or found that Catapult’s profits were attributable to the use of BioPoint’s trade secrets. These assertions are blatantly incorrect,” U.S. District Judge Richard G. Stearns wrote.

Click Here To Read The Full Article